Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 50

1.

Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes.

Chao BH, Lepeak L, Leal T, Robins HI.

Thrombosis. 2011;2011:530183. doi: 10.1155/2011/530183. Epub 2011 Apr 12.

PMID:
22084664
[PubMed]
Free PMC Article
2.

The heparins and cancer: review of clinical trials and biological properties.

Castelli R, Porro F, Tarsia P.

Vasc Med. 2004 May;9(3):205-13. Review.

PMID:
15675186
[PubMed - indexed for MEDLINE]
3.
4.

Anti-cancer properties of low-molecular-weight heparin: preclinical evidence.

Mousa SA, Petersen LJ.

Thromb Haemost. 2009 Aug;102(2):258-67. doi: 10.1160/TH08-12-0832. Review.

PMID:
19652876
[PubMed - indexed for MEDLINE]
5.

[Treatment of venous thromboembolic disease in cancer patients].

Farge-Bancel D, Florea L, Bosquet L, Debourdeau P.

Pathol Biol (Paris). 2008 Jun;56(4):220-8. doi: 10.1016/j.patbio.2008.02.007. Epub 2008 Apr 3. Review. French.

PMID:
18394821
[PubMed - indexed for MEDLINE]
6.

VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients.

Cohen AT, Nandini B, Wills JO, Ota S.

Thromb Res. 2010 Apr;125 Suppl 2:S21-9. doi: 10.1016/S0049-3848(10)70008-6. Review.

PMID:
20434000
[PubMed - indexed for MEDLINE]
7.

Management of venous thromboembolic disease. The impact of low-molecular-weight heparin.

Tapson VF, Hull RD.

Clin Chest Med. 1995 Jun;16(2):281-94. Review.

PMID:
7656540
[PubMed - indexed for MEDLINE]
8.

The role of low-molecular-weight heparins as supportive care therapy in cancer-associated thrombosis.

Cunningham RS.

Semin Oncol. 2006 Apr;33(2 Suppl 4):S17-25; quiz S41-2. Review.

PMID:
16638457
[PubMed - indexed for MEDLINE]
9.

Economic and practical aspects of thromboprophylaxis with unfractionated and low-molecular-weight heparins in hospitalized medical patients.

Pineo GF, Hull RD.

Clin Appl Thromb Hemost. 2009 Oct;15(5):489-500. doi: 10.1177/1076029609335910. Epub 2009 Jun 10. Review.

PMID:
19520676
[PubMed - indexed for MEDLINE]
10.

Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.

Romera-Villegas A, Cairols-Castellote MA, Vila-Coll R, Martí-Mestre X, Colomé E, Iguaz I.

Ann Vasc Surg. 2010 Jul;24(5):628-39. doi: 10.1016/j.avsg.2009.08.006. Epub 2009 Nov 25. Review.

PMID:
19932949
[PubMed - indexed for MEDLINE]
11.

Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care?

Burris HA 3rd.

Semin Oncol. 2006 Apr;33(2 Suppl 4):S3-16; quiz S41-2. Review.

PMID:
16638456
[PubMed - indexed for MEDLINE]
12.

Management of thrombosis in cancer: primary prevention and secondary prophylaxis.

Lee AY.

Br J Haematol. 2005 Feb;128(3):291-302. Review.

PMID:
15667530
[PubMed - indexed for MEDLINE]
13.

Prevention of venous thromboembolism in the cancer surgery patient.

Spyropoulos AC, Brotman DJ, Amin AN, Deitelzweig SB, Jaffer AK, McKean SC.

Cleve Clin J Med. 2008 Apr;75 Suppl 3:S17-26. Review.

PMID:
18496913
[PubMed - indexed for MEDLINE]
Free Article
14.

Established venous thromboembolism therapies: heparin, low molecular weight heparins, and vitamin K antagonists, with a discussion of heparin-induced thrombocytopenia.

Pendleton RC, Rodgers GM, Hull RD.

Clin Chest Med. 2010 Dec;31(4):691-706. doi: 10.1016/j.ccm.2010.07.003. Review.

PMID:
21047576
[PubMed - indexed for MEDLINE]
15.

Assessing, preventing, and treating venous thromboembolism: evidence-based approaches.

Nutescu EA.

Am J Health Syst Pharm. 2007 Jun 1;64(11 Suppl 7):S5-13. Review.

PMID:
17519445
[PubMed - indexed for MEDLINE]
16.

Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients.

Haas S.

Semin Thromb Hemost. 1999;25 Suppl 3:101-5. Review.

PMID:
10549724
[PubMed - indexed for MEDLINE]
17.

The effects of low molecular weight heparins on venous thromboembolism and survival in patients with cancer.

Lee AY.

Thromb Res. 2007;120 Suppl 2:S121-7. Review. Erratum in: Thromb Res. 2008;123(1):187-90.

PMID:
18023705
[PubMed - indexed for MEDLINE]
18.

Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.

Clark NP.

Thromb Res. 2008;123 Suppl 1:S58-61. doi: 10.1016/j.thromres.2008.08.005. Epub 2008 Sep 21. Review.

PMID:
18809206
[PubMed - indexed for MEDLINE]
19.

Management of venous thromboembolism.

de Moerloose P, Samama CM, Motte S.

Can J Anaesth. 2006 Jun;53(6 Suppl):S80-8. Review.

PMID:
16766793
[PubMed - indexed for MEDLINE]
20.

Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.

Holzheimer RG.

Eur J Med Res. 2004 Apr 30;9(4):225-39. Review.

PMID:
15210403
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk